Compare MSGM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | LPCN |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 19.1M |
| IPO Year | 2020 | 2011 |
| Metric | MSGM | LPCN |
|---|---|---|
| Price | $4.49 | $2.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.7K | ★ 38.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $741,000.00 | ★ $1,976,677.00 |
| Revenue This Year | $69.73 | N/A |
| Revenue Next Year | $146.81 | $92.00 |
| P/E Ratio | $74.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $1.81 |
| 52 Week High | $5.78 | $12.37 |
| Indicator | MSGM | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 42.28 |
| Support Level | $3.71 | $1.99 |
| Resistance Level | $4.73 | $2.30 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 69.75 | 32.00 |
Motorsport Games Inc is a racing game developer, publisher, and esports ecosystem provider of official motorsport racing series, including games based on the 24 Hours of Le Mans endurance race (Le Mans) and the associated FIA World Endurance Championship (the WEC). Its portfolio also includes the KartKraft karting simulation game, as well as Studio 397 B.V. (Studio397) and their rFactor 2 realistic racing simulator technology and platform. The games are developed and published for personal computers (PCs) through various digital channels, including full-game and downloadable content (DLC). Additionally, Motorsport Games organizes esports tournaments, competitions, and events. Its reportable segments are: Gaming, which generates the maximum revenue, and Esports.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.